Antihyperalgesic and antiallodynic effect of sirolimus in neuropathic pain and the role of cytokines in this effect

Neuroscience Letters

Volumn 481, Issue 1, 2010, Pages 17-20

  Orhan, Cahide Elif ^a   Önal, Aytül ^a   Ülker, Sibel ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Cytokine; Interleukin 1beta; Interleukin 6; Neuropathic pain; Rat; Sirolimus; Tumor necrosis factor alpha

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; IMMUNOLOGIC FACTOR;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; HYPERALGESIA; LIGATION; LOCOMOTION; MALE; NERVE INJURY; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SPINAL CORD; TREATMENT OUTCOME; WESTERN BLOTTING; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENZYME ASSAY; METABOLISM; PAIN THRESHOLD; PROCEDURES; SCIATICA; TIME; WISTAR RAT;

ANALYSIS OF VARIANCE; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ASSAYS; HYPERALGESIA; IMMUNOLOGIC FACTORS; MALE; PAIN THRESHOLD; RATS; RATS, WISTAR; SCIATICA; SIROLIMUS; SPINAL CORD; TIME FACTORS;

EID: 77955087125     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.06.039     Document Type: Article

References (27)

1. Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988, 33:87-107.
2. Carlson R.P., Hartman D.A., Ochalski S.J., Zimmerman J.L., Glaser K.B. Sirolimus (rapamycin, Rapamune®) and combination therapy with cyclosporin A in the rat developing adjuvant arthritis model: correlation with blood levels and the effects of different oral formulations. Inflamm. Res. 1998, 47:339-344.
3. Cattaneo D., Cortinovis M., Baldelli S., Gotti E., Remuzzi G., Perico N. Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen. J. Clin. Pharmacol. 2009, 49:773-781.
4. Chabot S., Williams G., Yong V.W. Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b. J. Clin. Invest. 1997, 100:604-612.
5. Covey W.C., Ignatowski T.A., Renauld A.E., Knight P.R., Nader N.D., Spengler R.N. Expression of neuron-associated tumor necrosis factor alpha in the brain is increased during persistent pain. Reg. Anesth. Pain Med. 2002, 27:357-366.
6. Cui J.G., Holmin S., Mathiesen T., Meyerson B.A., Linderoth B. Possible role of inflammatory mediators in tactile hypersensitivity in rat. Pain 2000, 88:239-248.
7. Donia M., Mangano K., Amoroso A., Mazzarino M.C., Imbesi R., Castrogiovanni P., Coco M., Meroni P., Nicoletti F. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells. J. Autoimmun. 2009, 33:135-140.
8. Ekberg H., Mamelok R.D., Pearson T.C., Vincenti F., Tedesco-Silva H., Daloze P. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. Transplantation 2009, 87:1360-1366.
9. Hattori A., Tanaka E., Murase K., Ishida N., Chatani Y., Tsujimoto M., Hayashi K., Cono M. Tumor necrosis factor stimulates the synthesis and secretion of biologically active nerve growth factor in non-neuronal cells. J. Biol. Chem. 1993, 268:2577-2582.
10. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
11. Lee H.L., Lee K.M., Son S.J., Hwang S.H., Cho H.J. Temporal expression of cytokines and their receptors mRNAs in a neuropathic pain model. Neuroreport 2004, 15:2807-2811.
12. Martucci C., Trovato A.E., Costa B., Borsani E., Franchi S., Magnaghi V., Panerai A.E., Rodella L.F., Valsecchi A.E., Sacerdote P., Colleoni M. The purinergic antagonist PPADS reduces pain related behaviours and interleukin-1 beta, interleukin-6, iNOS and nNOS overproduction in central and peripheral nervous system after peripheral neuropathy in mice. Pain 2008, 137:81-95.
13. Mika J Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol. Rep. 2008, 60:297-307.
14. Moalem G., Tracey D.J. Immune and inflammatory mechanisms in neuropathic pain. Brain Res. Rev. 2006, 51:240-264.
15. Moalem G., Xu K., Yu L. T lymphocytes play a role in neuropathic following peripheral nerve injury in rats. Neuroscience 2004, 129:767-777.
16. Ramzy D., Rao V., Tumiati L.C., Xu N., Miriuka S., Delgado D., Ross H.J. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine. Circulation 2006, 114:I214-I219.
17. Randall L.O., Selitto J.J. A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. Ther. 1957, 111:409-418.
18. Riazi K., Galic M.A., Kuzmiski J.B., Ho W., Sharkey K.A., Pittman Q.J. Microglial activation and TNFα production mediate altered CNS excitability following peripheral inflammation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:17151-17156.
19. Sehgal S.N. Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biochem. 1998, 31:335-340.
20. Terada N., Lucas J.J., Szepesi A., Franklin R.A., Domenico J., Gelfand E.W. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J. Cell. Physiol. 1993, 154:7-15.
21. Thacker M.A., Dip G., Clark A.K., Marchand F., Stephen M. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth. Analg. 2007, 105:838-847.
22. Tracey D.J., Walker J.S. Pain due to nerve damage: are inflammatory mediators involved?. Inflamm. Res. 1995, 44:407-411.
23. Vassalli P. The pathophysiology of tumor necrosis factors. Ann. Rev. Immunol. 1992, 10:411-452.
24. Watkins L.R., Goehler L.E., Relton J., Brewer M.T., Maier S.F. Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia. Brain Res. 1995, 692:244-250.
25. Wieseler-Frank J., Maier S.F., Watkins L.R. Immune-to-brain communication dynamically modulates pain: Physiological and pathological consequences. Brain Behav. Immun. 2005, 19:104-111.
26. Zimmermann M. Pathobiology of neuropathic pain. Eur. J. Pharmacol. 2001, 429:23-37.
27. Zimmerman J.J., Kahan B.D. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J. Clin. Pharmacol. 1997, 37:405-415.